Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001772640 | SCV001993225 | uncertain significance | not provided | 2023-02-15 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001772640 | SCV002202019 | benign | not provided | 2024-08-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163844 | SCV003877489 | uncertain significance | Inborn genetic diseases | 2023-02-16 | criteria provided, single submitter | clinical testing | The c.3446A>G (p.N1149S) alteration is located in exon 46 (coding exon 46) of the COL11A2 gene. This alteration results from a A to G substitution at nucleotide position 3446, causing the asparagine (N) at amino acid position 1149 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004749730 | SCV005357136 | uncertain significance | COL11A2-related disorder | 2024-05-10 | no assertion criteria provided | clinical testing | The COL11A2 c.3446A>G variant is predicted to result in the amino acid substitution p.Asn1149Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0042% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |